MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
308.16
-1.73
-0.56%
After Hours: 309.24 +1.08 +0.35% 19:53 06/21 EDT
OPEN
313.13
PREV CLOSE
309.89
HIGH
313.44
LOW
307.29
VOLUME
6.93M
TURNOVER
0
52 WEEK HIGH
329.72
52 WEEK LOW
211.82
MARKET CAP
165.31B
P/E (TTM)
44.03
1D
5D
1M
3M
1Y
5Y
Invest (Nearly) Stress-Free With SCHD
Schwab U.S. Dividend Equity ETF™ is a conservative fund that offers stable growth and dividend growth. The SCHD ETF holds 103 diversified holdings, with the top sectors being financials, healthcare, and technology. SCHD is not suitable for high-growth or high-yield investors.
Seeking Alpha · 15h ago
UPDATE 1-US FDA approves Roche's drug for a chronic blood disorder
US FDA approves Roche's drug for a chronic blood disorder. The drug crovalimab, branded as PiaSky, is a monthly treatment for paroxysmal hemoglobinuria. PNH is a disorder in which red blood cells break apart prematurely. The disease affects around 20,000 people worldwide.
Reuters · 15h ago
ProShares UltraPro QQQ Experiences Big Outflow
NASDAQ · 18h ago
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences, Inc. (NASDAQ:GILD) has been the subject of speculation about its potential involvement in the obesity drug market. The biotech company is renowned for its cancer and HIV treatments. But, Gilead says its focus remains on liver treatments.
Benzinga · 20h ago
Possible Bearish Signals With Amgen Insiders Disposing Stock
Amgen Inc. Insiders have sold US$2.7m worth of shares in the last year. The biggest single sale was 37% of Jonathan Graham's stake in Amgen. The last three months saw significant insider selling at Amgen, but there were no purchases. Amgen insiders own 0.2% of the company. It is good to see an insider sale of shares over the last 12 months. But Amgen isn't the best stock to buy. You can see the insider transactions of Amgen and its share price.
Simply Wall St · 21h ago
Nektar Therapeutics Likely To Drift And Wobble Ahead Of Key Phase II Data In 2025
Seeking Alpha · 1d ago
Where Will Amgen Be in 5 Years?
Amgen's shares have risen by more than 70% in five years. The drugmaker's biggest product is a weight loss drug called MariTide. The company's debt is a concern for investors, but the company's growth prospects are encouraging. Amgen is trading at 15 times its estimated future profits.
The Motley Fool · 2d ago
M&A Is Back. 4 Stocks That Could Be Targets.
Barron‘s · 3d ago
More
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.